Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 15, 2012

View Archived Issues

Safety results presented from the AMETHYST-DN study

Scientists at Myrexis synthesize new IKK-epsilon inhibitors

Gilead Sciences patents novel antiviral agents

New vaccines for tuberculosis disclosed by Alarum Development

Genmab presents novel bispecific antibodies for cancer

Allergan patents new S1P1 receptor agonists

Novel agents for HIV infection synthesized by Bristol-Myers Squibb

New antimalarial agents prepared at The Broad Institute

Brodalumab does not demonstrate meaningful clinical efficacy in patients with RA

Antitumor efficacy demonstrated for PF-05082566 in mouse model

Further data published on BAY-1000394

Phase IIb trial of AM-111 in severe hearing loss meets primary endpoint

Japanese team develops novel MAPK inhibitor for autoimmune diseases

Phase III trial of rivaroxaban for secondary prevention of cardiac events begins

PDUFA date set for Lymphoseek NDA resubmission

Interim results for CVax show encouraging immune response

Data monitoring committee recommends continuation of phase I NBTXR-3 trial

Can-Fite BioPharma to develop CF-602 for sexual dysfunction

AtheroNova partner files IND in Russia for AHRO-001

Diazyme obtains FDA clearance for use of kidney disease biomarker test

Bristol-Myers Squibb and AstraZeneca gain European approval for dapagliflozin

Committee recommends completion of PICASSO 3 trial as planned

Transgene and EORTC to collaborate on phase IIb trial of TG-4001

Pacific Therapeutics reports encouraging phase I results with combination treatment for fibrosis

Daiichi Sankyo files application in Japan for use of Inavir in prevention of influenza infection

European orphan product designation granted to algenpantucel-L

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...